Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -419.4%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $10M | $66M | — | — | — | — |
| Enterprise Value | $-663229 | $8M | $62M | — | — | — | — |
| P/E Ratio → | -0.10 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 0.32 | 1.63 | 24.04 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -419.4% | -419.4% | -559.7% | -1315.6% | — | — | — |
| ROA | -143.1% | -143.1% | -79.0% | -198.1% | -193.5% | -338.0% | — |
| ROIC | -839.4% | -839.4% | — | — | -774.6% | — | — |
| ROCE | -287.6% | -287.6% | -432.2% | -4570.2% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.39 | 0.39 | 3.86 | 1.39 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.40 | -1.25 | -5.92 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -90.40 | -90.40 | -557.05 | -111.14 | -6.83 | -394.50 | — |
Net cash position: cash ($5M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 3.61 | 3.61 | 1.12 | 1.00 | 0.37 | 0.27 | — |
| Quick Ratio | 3.61 | 3.61 | 1.12 | 1.00 | 0.37 | 0.27 | — |
| Cash Ratio | 2.78 | 2.78 | 1.10 | 1.00 | 0.32 | 0.23 | — |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $2M | $2M | $2M | $2M | $2M | $2M |
Critical liquidity and dilution
Based on recent financial filings, FBLG trades at a price-to-book ratio of 0.30, a valuation level that suggests the market is heavily discounting the company's intellectual property portfolio due to the extreme urgency of its liquidity requirements and the high probability of near-term equity dilution.
The current P/B multiple significantly trails industry peers, indicating that investors are assigning little value to the company's patent estate relative to its liquidation risk. This valuation gap implies that the market is prioritizing the immediate cash runway over the long-term potential of the fibroblast platform.
As reported in quarterly financial statements, FBLG's ROIC has remained deeply negative, reaching -108.3% in 2026Q1, which highlights the company's current inability to generate productive returns on invested capital while it remains in a capital-intensive, pre-revenue clinical development phase for its lead therapeutic candidates.
The persistent decay in ROIC reflects the high cost of clinical trial execution without any offsetting commercial revenue. This trend suggests that capital is being consumed to build intangible assets rather than to generate operational returns, a common but precarious profile for early-stage biotechnology firms.
According to recent SEC filings, the company's current ratio has fluctuated significantly, settling at 1.59 in 2026Q1, yet this figure masks a rapidly depleting cash position that leaves the firm with minimal flexibility to navigate unexpected clinical trial delays or adverse regulatory developments in the near term.
The volatility in the current ratio, which dropped from 3.61 in 2025Q4 to 1.59 in 2026Q1, indicates a rapid consumption of working capital. Investors should monitor this trend closely, as the current liquidity profile appears insufficient to sustain operations through the next major clinical milestone without external financing.
Based on the latest balance sheet data, FBLG's debt-to-equity ratio rose to 0.86 in 2026Q1, a concerning shift that suggests the company is increasingly relying on debt to bridge its funding gaps, thereby adding interest-related pressure to an already strained and cash-burning operational structure.
While the debt-to-equity ratio remains lower than some peers, the upward trend in leverage during a period of negative cash flow warrants caution. This reliance on debt, combined with a lack of revenue, suggests that the company's financial stability is highly sensitive to interest rate fluctuations and credit availability.
As indicated by the company's financial statements, the use of P/E ratios to evaluate FBLG is fundamentally flawed, as the firm lacks the recurring earnings necessary for such a metric to provide any meaningful insight into its true economic value or its long-term commercial viability.
Investors should instead focus on the cash-runway-to-milestone ratio, which better captures the company's operational survival risk. Relying on P/E multiples in this context obscures the reality that the firm's value is derived from clinical trial success rather than current profitability, leading to potentially misleading investment conclusions.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FBLG stock.
FibroBiologics, Inc. Common Stock's current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
FibroBiologics, Inc. Common Stock's return on equity (ROE) is -419.4%. The historical average is -419.4%.
Based on historical data, FibroBiologics, Inc. Common Stock is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.